Health Technology Solutions, Inc. and Advanced Molecular Services Group, Inc. entered into an agreement to acquire InnovaQor, Inc. in a reverse merger transaction on June 10, 2020. As per the agreement, Rennova Health will merge Health Technology Solutions and Advanced Molecular Services into a newly formed public company to be called InnovoQor Inc. TPT shareholders will receive approximately 2.5 million common shares in InnovaQor, with TPT receiving and retaining directly an additional 2.5 million common shares (total 5 million common shares) and Rennova Health, Inc. (OTCPK : RNVA) receiving approximately $22 million of preferred shares, $5 million of which will be converted to common shares and distributed to Rennova Shareholders upon completion of the relevant registration/approvals with the SEC, and with the remaining approximately $17 million of preferred shares held by Rennova as an investment in InnovaQor and convertible to common shares on achievement of certain milestones going forward. It is intended that 1 million common shares will vest to management. As of January 6, 2021, Rennova Health completed an agreement with InnovaQor, Inc. to merge its software and genetic testing interpretation divisions, Health Technology Solutions, Inc. and Advanced Molecular Services Group, Inc., and their subsidiaries into InnovaQor. After closing these entities will operate as wholly owned subsidiaries of InnovaQor. Upon the completion of the transaction, TPT will become a minority interest owner in InnovoQor and InnovoQor will become a public company. Rennova will be responsible to appoint management to the combined company. The Directors and Officers of InnovoQor will be as established by Rennova. The Board will also include two TPT approved Directors. The agreement can be terminated by parties under certain circumstances. The transaction is subject to a number of approvals and consents which need to be secured to complete the transaction including relevant SEC approvals, any required governmental or third party approvals shall have obtained, the stockholders of public company and stockholders of Health Technology Solutions, Inc. and Advanced Molecular Services Group, Inc. shall have obtained the agreement terms, Health Technology Solutions, Inc. and Advanced Molecular Services Group, Inc. shall have delivered to TPT audited financial statements and balance sheets. The transaction is expected to be completed by the third quarter of 2020. As of January 6, 2021, the transaction is expected to close on or before January 31, 2021. J. Thomas Cookson of Shutts & Bowen LLP acted as legal advisor to Rennova Health, Inc. Health Technology Solutions, Inc. and Advanced Molecular Services Group, Inc. cancelled the acquisition of InnovaQor, Inc. in a reverse merger transaction on March 5, 2021. The parties had worked for a number of months to close the agreement but unfortunately could not reach final terms on a number of closing items and have agreed to immediately terminate it. Each party will continue independently with their own business strategy and plan.